cvs caremark tirzepatide expands coverage options for GLP-1s In 2025, CVS Caremark excluded

Non-GLP therapies may be considered for patients who: Are not candidates for GLP-1 medications Prefer non-injectable treatment options Have experienced side effects with other therapies Are seeking medically supervised weight management support A licensed clinician will determine the most appropriate treatment approach based on medical history, current conditions, and overall health goals

Quality and regulation are major concernscompounded drugs are not FDA-approved

Retrieved June 11, 2025, from Swiss Medica

Participants had a mean age of 47.3 years, 82.9% were female and the mean body mass index (BMI) at enrolment was 41.5